ACCELERATE DIAGNOSTICS INC (AXDX)
US00430H2013 - Common Stock
Overall AXDX gets a fundamental rating of 1 out of 10. We evaluated AXDX against 193 industry peers in the Health Care Equipment & Supplies industry. AXDX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, AXDX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AXDX has reported negative net income.
AXDX had a negative operating cash flow in the past year.
In the past 5 years AXDX always reported negative net income.
AXDX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
AXDX has a worse Return On Assets (-196.48%) than 93.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -196.48% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-128.73%
ROA(5y)-106.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AXDX's Gross Margin of 30.97% is on the low side compared to the rest of the industry. AXDX is outperformed by 72.92% of its industry peers.
AXDX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AXDX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.13%
GM growth 5Y-6.67%
2. Health
2.1 Basic Checks
AXDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AXDX has been increased compared to 1 year ago.
AXDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for AXDX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -34.32, we must say that AXDX is in the distress zone and has some risk of bankruptcy.
AXDX has a worse Altman-Z score (-34.32) than 92.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -34.32 |
ROIC/WACCN/A
WACC4.37%
2.3 Liquidity
A Current Ratio of 2.03 indicates that AXDX has no problem at all paying its short term obligations.
AXDX has a Current ratio of 2.03. This is in the lower half of the industry: AXDX underperforms 73.96% of its industry peers.
A Quick Ratio of 1.76 indicates that AXDX should not have too much problems paying its short term obligations.
AXDX has a worse Quick ratio (1.76) than 64.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.03 | ||
| Quick Ratio | 1.76 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 51.58% over the past year.
The Revenue has decreased by -5.44% in the past year.
The Revenue has been growing by 16.29% on average over the past years. This is quite good.
EPS 1Y (TTM)51.58%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q42.14%
Revenue 1Y (TTM)-5.44%
Revenue growth 3Y2.59%
Revenue growth 5Y16.29%
Revenue growth Q2Q1.92%
3.2 Future
AXDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.92% yearly.
AXDX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.80% yearly.
EPS Next Y37.08%
EPS Next 2Y20.92%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-2.1%
Revenue Next 2Y7.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AXDX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AXDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AXDX's earnings are expected to grow with 20.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.92%
EPS Next 3YN/A
5. Dividend
5.1 Amount
AXDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACCELERATE DIAGNOSTICS INC
NASDAQ:AXDX (5/3/2024, 7:00:01 PM)
After market: 0.98 +0.06 (+5.97%)0.9248
-0.02 (-1.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap20.03M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -196.48% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 30.97% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.03 | ||
| Quick Ratio | 1.76 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)51.58%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y37.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-5.44%
Revenue growth 3Y2.59%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y